Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Non-blind, Single-center Study to Evaluate the Safety and Tolerability of Rituximab Down-regulating Immunoglobulin (Ig) Treatment in Children With Duchenne Muscular Dystrophy (DMD) Who Can Walk

NCT07475754 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT07475754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07475754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Non-blind, Single-center Study to Evaluate the Safety and Tolerability of Rituximab Down-regulating Immunoglobulin (Ig) Treatment in Children With Duchenne Muscular Dystrophy (DMD) Who Can Walk
Lead sponsor
Peking Union Medical College Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
March 23, 2026
Completion date
April 23, 2027
Enrollment
5 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy (dmd)